Business Wire

ENEOS, Toyota, and Woven Planet Collaborate to Facilitate CO 2 -free Hydrogen Production and Usage for Woven City and Beyond

Share

ENEOS Corporation (ENEOS) and Toyota Motor Corporation (Toyota) have signed a joint agreement to explore CO2-free hydrogen production and usage at Woven City, the prototype city of the future that Toyota has started to develop in Susono City, Shizuoka Prefecture, Japan. Together with Toyota’s subsidiary Woven Planet Holdings, Inc. (Woven Planet), they will accelerate efforts by managing technical logistics.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322006181/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

As described in the Basic Agreement signed in 2021, ENEOS and Toyota have decided to commence construction and operation of a hydrogen refueling station in close proximity to Woven City to produce and supply CO2-free hydrogen to Woven City and Fuel Cell Electric Vehicles (FCEVs) (Item 1 and 2 set forth below). Together, they will also research and design an efficient hydrogen supply and demand management system (Item 3 described below). The ENEOS hydrogen refueling station is scheduled to begin operations before the opening of Woven City in 2024-2025.

Items to be considered at the time of the Basic Agreement*1

  1. ENEOS to establish and operate a hydrogen refueling station in close proximity to Woven City
  2. ENEOS to produce "green hydrogen," hydrogen derived from renewable energy, by electrolyzers at the aforementioned station and supply it to Woven City to be used at a stationary fuel cell generator that will be installed within Woven City by Toyota
  3. Promote the use of hydrogen-powered fuel cell mobility for logistics in and nearby Woven City. Validate a base unit*2 of hydrogen demand for those mobility logistics as well as build a supply and demand management system
  4. Conduct joint advanced research on hydrogen supply at the demonstration hub to be established within Woven City

Items that have been decided in the joint development agreement this time

Item 1)

- Construct a hydrogen refueling station adjacent to Woven City

(Scheduled to be constructed at 1576-3, Mishuku Aza Hounokidaira, Susono-city, Shizuoka-Pref., Japan)

Item 2)

- Install electrolyzers at the hydrogen refueling station, which will produce CO2-free hydrogen using electricity generated by renewable energy

- Supply CO2-free hydrogen to not only various FCEVs from passenger cars to commercial vehicles but also to Woven City using a pipeline

- Install a stationary fuel cell generator at the hydrogen refueling station in case of a power outage*3

Item 3)

- Consider connecting the Community Energy Management System (CEMS) of Woven City with the hydrogen EMS of ENEOS to optimize hydrogen production

The ENEOS hydrogen refueling station will “produce” the hydrogen that will meet the energy needs of “users,” FCEVs in and around Woven City and Woven City as well. This collaboration expedites our progress toward realizing a truly carbon-neutral society and will facilitate and normalize clean energy operations first at Woven City and eventually the world.

Woven City is the project of Toyota aiming to create happiness through mobility of "people," "goods," and "information." It is focused on three pillars. That are: Human-Centered City that makes people happier in their everyday lives, considering the needs of different kinds of people before and during the development of technology; Living Laboratory, the first-of-its-kind test track for mobility where researchers, engineers, and scientists demonstrate innovative ideas and future technologies both virtually and in the real world; and Ever-Evolving City, rooted in Toyota’s kaizen (continuous improvement) approach, is focused on new ideas that provide better mobility of information, goods, and people.

*1 Announced on May 10, 2021 “ENEOS and Toyota Come Together to Make Woven City the Most Hydrogen-Based Society”
*2 Hydrogen can be supplied to FCEVs even during power outages by using stored hydrogen to operate a hydrogen refueling system with a stationary fuel cell generator. This allows the external power supply function of FCEVs to be utilized to provide power support where electricity is needed.
*3 The "base unit" is a standard of measurement required to ensure a result that is both practically valuable to users and commercially viable.

About ENEOS Corporation
Under ENEOS Holdings, Inc., the ENEOS Group has developed businesses in the energy and nonferrous metals segments, from upstream to downstream. The Group's envisioned goals for 2040 are: becoming one of the most prominent and internationally-competitive energy and materials company groups in Asia, creating value by transforming our current business structure, and contributing to the development of a low-carbon, recycling-oriented society with the pursuit of carbon-neutral status in its own CO2 emissions. ENEOS Corporation, one of the principal operating companies in the Group, is contributing to achievement of the Group's envisioned goals through a broad range of energy businesses.
https://www.hd.eneos.co.jp/english/
https://www.eneos.co.jp/english/

About Toyota Motor Corporation
Toyota Motor Corporation (Toyota) (NYSE: TM) is the global mobility company that introduced the Prius hybrid-electric car in 1997 and the first mass-produced fuel cell sedan, Mirai, in 2014. Headquartered in Toyota City, Japan, Toyota has been making cars since 1937. Today, Toyota proudly employs 370,000 employees in communities around the world. Together, they build around 10 million vehicles per year in 28 countries and regions, from mainstream cars and premium vehicles to mini-vehicles and commercial trucks, and sell them in more than 170 countries and regions under the brands Toyota, Lexus, Daihatsu and Hino.
For more information, please visit https://global.toyota/en

Woven Planet
Woven Planet is building the safest mobility in the world. A subsidiary of Toyota, Woven Planet innovates and invests in new technologies, software, and business models that transform how we live, work and move. With a focus on automated driving, smart cities, robotics and more, Woven Planet builds on Toyota's legacy of trust to deliver secure, connected, reliable, and sustainable mobility solutions for all.
Learn more at woven-planet.global.

End

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Woven Planet Holdings, Inc.
Public Relations
pr@woven-planet.global
https://www.woven-planet.global

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination

Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib

New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release

Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet

Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release

On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan

Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release

Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom